Dysregulated inflammation may predispose patients with serious mental illnesses to severe COVID‑19 (Review)
- Authors:
- Sergej Nadalin
- Hrvoje Jakovac
- Vjekoslav Peitl
- Dalibor Karlović
- Alena Buretić‑Tomljanović
-
Affiliations: Department of Medical Biology and Genetics, Faculty of Medicine, University of Rijeka, 51000 Rijeka, Croatia, Department of Physiology and Immunology, Faculty of Medicine, University of Rijeka, 51000 Rijeka, Croatia, Department of Psychiatry, Sestre Milosrdnice University Hospital Center and Catholic University of Croatia, 10000 Zagreb, Croatia - Published online on: June 28, 2021 https://doi.org/10.3892/mmr.2021.12250
- Article Number: 611
-
Copyright: © Nadalin et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
 |
|
Roberts CM, Levi M, McKee M, Schilling R, Lim WS and Grocott MPW: COVID-19: A complex multisystem disorder. Br J Anaesth. 125:238–242. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Chacko M, Job A, Caston F III, George P, Yacoub A and Cáceda R: COVID-19-induced psychosis and suicidal behavior: Case report. SN Compr Clin Med. 26:1–5. 2020.PubMed/NCBI | |
|
Ferrando SJ, Klepacz L, Lynch S, Tavakkoli M, Dornbush R, Baharani R, Smolin Y and Bartell A: COVID-19 psychosis: A potential new neuropsychiatric condition triggered by novel coronavirus infection and the inflammatory response? Psychosomatics. 6:551–555. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Mazza MG, De Lorenzo R, Conte C, Poletti S, Vai B, Bollettini I, Melloni EMT, Furlan R, Ciceri F, Rovere-Querini P, et al: Anxiety and depression in COVID-19 survivors: Role of inflammatory and clinical predictors. Brain Behav Immun. 89:594–600. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Anjum S, Ullah R, Rana MS, Khan HA, Memon FS, Ahmed Y, Jabeen S and Faryal R: COVID-19 pandemic: A serious threat for public mental health globally. Psychiatr Danub. 32:245–250. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
El-Khoury F, Cuenca M, Niel P and Masson VD: Low prevalence of SARS-CoV-2 among patients presenting at a Parisian psychiatry University Hospital Group. Eur J Psychiatry. Sep 24–2020.(Epub ahead of print). View Article : Google Scholar : PubMed/NCBI | |
|
Lee SW, Yang JM, Moon SY, Yoo IK, Ha EK, Kim SY, Park UM, Choi S, Lee SH, Ahn YM, et al: Association between mental illness and COVID-19 susceptibility and clinical outcomes in South Korea: A nationwide cohort study. Lancet Psychiatry. 7:1025–1031. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
DiMatteo MR, Lepper HS and Croghan TW: Depression is a risk factor for noncompliance with medical treatment: Meta-analysis of the effects of anxiety and depression on patient adherence. Arch Intern Med. 160:2101–2107. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Nicholson A, Kuper H and Hemingway H: Depression as an aetiologic and prognostic factor in coronary heart disease: A meta-analysis of 6362 events among 146 538 participants in 54 observational studies. Eur Heart J. 27:2763–2774. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Alpert O, Begun L, Garren P and Solhkhah R: Cytokine storm induced new onset depression in patients with COVID-19. A new look into the association between depression and cytokines-two case reports. Brain Behav Immun Health. 9:1001732020. View Article : Google Scholar : PubMed/NCBI | |
|
Maugeri G, Castrogiovanni P, Battaglia G, Pippi R, D'Agata V, Palma A, Di Rosa M and Musumeci G: The impact of physical activity on psychological health during Covid-19 pandemic in Italy. Heliyon. 6:e043152020. View Article : Google Scholar : PubMed/NCBI | |
|
Ravalli S and Musumeci G: Coronavirus outbreak in Italy: Physiological benefits of home-based exercise during pandemic. J Funct Morphol Kinesiol. 5:312020. View Article : Google Scholar : PubMed/NCBI | |
|
Maugeri G and Musumeci G: Adapted physical activity to ensure the physical and psychological well-being of COVID-19 patients. J Funct Morphol Kinesiol. 6:132021. View Article : Google Scholar : PubMed/NCBI | |
|
Weir EK, Thenappan T, Bhargava M and Chen Y: Does vitamin D deficiency increase the severity of COVID-19? Clin Med (Lond). 20:e107–e108. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Leisman DE, Ronner L, Pinotti R, Taylor MD, Sinha P, Calfee CS, Hirayama AV, Mastroiani F, Turtle CJ, Harhay MO, et al: Cytokine elevation in severe and critical COVID-19: A rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes. Lancet Respir Med. 8:1233–1244. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Goldstein BI, Kemp DE, Soczynska JK and McIntyre RS: Inflammation and the phenomenology, pathophysiology, comorbidity, and treatment of bipolar disorder: A systematic review of the literature. J Clin Psychiatry. 70:1078–1090. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Farooq RK, Asghar K, Kanwal S and Zulqernain A: Role of inflammatory cytokines in depression: Focus on interleukin-1β. Biomed Rep. 6:15–20. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Himmerich H, Patsalos O, Lichtblau N, Ibrahim MAA and Dalton B: Cytokine research in depression: Principles, challenges, and open questions. Front Psychiatry. 10:302019. View Article : Google Scholar : PubMed/NCBI | |
|
Momtazmanesh S, Zare-Shahabadi A and Rezaei N: Cytokine alterations in schizophrenia: An updated review. Front Psychiatry. 10:8922019. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang J, Lu H, Zeng H, Zhang S, Du Q, Jiang T and Du B: The differential psychological distress of populations affected by the COVID-19 pandemic. Brain Behav Immun. 87:49–50. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Stienen MN, Haghikia A, Dambach H, Thöne J, Wiemann M, Gold R, Chan A, Dermietzel R, Faustmann PM, Hinkerohe D and Prochnow N: Anti-inflammatory effects of the anticonvulsant drug levetiracetam on electrophysiological properties of astroglia are mediated via TGFβ1 regulation. Br J Pharmacol. 162:491–507. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Hoşgörler F, Keleş D, Tanrıverdi-Akhisaroğlu S, İnanç Ş, Akhisaroğlu M, Cankurt Ü, Aydoğdu Z, Uçar AD, Çetinayak O, Oktay G and Arda SG: Anti-inflammatory and Anti-apoptotic effect of valproic acid and doxycycline independent from MMP inhibition in early radiation damage. Balkan Med J. 33:488–495. 2013. View Article : Google Scholar | |
|
Al-Amin MM, Nasir Uddin MM and Mahmud Reza H: Effects of antipsychotics on the inflammatory response system of patients with schizophrenia in peripheral blood mononuclear cell cultures. Clin Psychopharmacol Neurosci. 11:144–151. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Fourrier C, Sampson E, Mills NT and Baune BT: Anti-inflammatory treatment of depression: Study protocol for a randomised controlled trial of vortioxetine augmented with celecoxib or placebo. Trials. 19:4472018. View Article : Google Scholar : PubMed/NCBI | |
|
Cho M, Lee TY, Kwak YB, Yoon YB, Kim M and Kwon JS: Adjunctive use of anti-inflammatory drugs for schizophrenia: A meta-analytic investigation of randomized controlled trials. Aust N Z J Psychiatry. 53:742–759. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
May M, Slitzky M, Rostama B, Barlow D and Houseknecht KL: Antipsychotic-induced immune dysfunction: A consideration for COVID-19 risk. Brain Behav Immun Health. 6:1000972020. View Article : Google Scholar : PubMed/NCBI | |
|
Govind R, Fonseca de Freitas D, Pritchard M, Hayes RD and MacCabe JH: Clozapine treatment and risk of COVID-19 infection: Retrospective cohort study. Br J Psychiatry. 27:1–7. 2020.PubMed/NCBI | |
|
Gurrera RJ and Perry NL: Clozapine-associated aspiration pneumonia: Case series and review of the literature: Reply. Psychosomatics. 60:1032019. View Article : Google Scholar : PubMed/NCBI | |
|
Ponsford M, Castle D, Tahir T, Robinson R, Wade W, Steven R, Bramhall K, Moody M, Carne E, Ford C, et al: Clozapine is associated with secondary antibody deficiency. Br J Psychiatry. 214:1–7. 2018.PubMed/NCBI | |
|
Vancampfort D, Probst M, Daenen A, Damme TV, De Hert M, Rosenbaum S and Bruyninckx D: Impact of antipsychotic medication on physical activity and physical fitness in adolescents: An exploratory study. Psychiatry Res. 242:192–197. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Perez-Cruzado D, Cuesta-Vargas A, Vera-Garcia E and Mayoral-Cleries F: Medication and physical activity and physical fitness in severe mental illness. Psychiatry Res. 267:19–24. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Brailovskaia J, Cosci F, Mansueto G, Miragall M, Herrero R, Baños RM, Krasavtseva Y, Kochetkov Y and Margraf J: The association between depression symptoms, psychological burden caused by Covid-19 and physical activity: An investigation in Germany, Italy, Russia, and Spain. Psychiatry Res. 295:1135962021. View Article : Google Scholar : PubMed/NCBI | |
|
Phillips C: Brain-Derived neurotrophic factor, depression, and physical activity: Making the neuroplastic connection. Neural Plast. 2017:72601302017. View Article : Google Scholar : PubMed/NCBI | |
|
Köhler-Forsberg O, N Lydholm C, Hjorthøj C, Nordentoft M, Mors O and Benros ME: Efficacy of anti-inflammatory treatment on major depressive disorder or depressive symptoms: Meta-analysis of clinical trials. Acta Psychiatr Scand. 139:404–419. 2019. View Article : Google Scholar | |
|
Lenze EJ, Mattar C, Zorumski CF, Stevens A, Schweiger J, Nicol GE, Miller JP, Yang L, Yingling M, Avidan MS and Reiersen AM: Fluvoxamine vs placebo and clinical deterioration in outpatients with symptomatic COVID-19: A randomized clinical trial. JAMA. 324:2292–2300. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Ishima T, Fujita Y and Hashimoto K: Interaction of new antidepressants with sigma-1 receptor chaperones and their potentiation of neurite outgrowth in PC12 cells. Eur J Pharmac. 727:167–173. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Homolak J and Kodvanj I: Widely available lysosome targeting agents should be considered as potential therapy for COVID-19. Int J Antimicrob Agents. 56:1060442020. View Article : Google Scholar : PubMed/NCBI | |
|
Nadkarni S and Devinsky O: Psychotropic effects of antiepileptic drugs. Epilepsy Curr. 5:176–181. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Grunze HC: The effectiveness of anticonvulsants in psychiatric disorders. Dialogues Clin Neurosci. 10:77–89. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Aranow C: Vitamin D and the immune system. J Investig Med. 59:881–886. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Menon B and Harinarayan CV: The effect of anti epileptic drug therapy on serum 25-hydroxyvitamin D and parameters of calcium and bone metabolism-a longitudinal study. Seizure. 19:153–158. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Teagarden DL, Meador KJ and Loring DW: Low vitamin D levels are common in patients with epilepsy. Epilepsy Res. 108:1352–1356. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Chaudhuri JR, Mridula KR, Rathnakishore C, Balaraju B and Bandaru VS: Association of 25-Hydroxyvitamin D Deficiency in pediatric epileptic patients. Iran J Child Neurol. 11:48–56. 2017.PubMed/NCBI | |
|
Mariani J, Giménez VMM, Bergam I, Tajer C, Antonietti L, Inserra F, Ferder L and Manucha W: Association between vitamin D deficiency and COVID-19 incidence, complications, and mortality in 46 countries: An ecological study. Health Secur. 19:302–308. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Jain A, Chaurasia R, Sengar NS, Singh M, Mahor S and Narain S: Analysis of vitamin D level among asymptomatic and critically ill COVID-19 patients and its correlation with inflammatory markers. Sci Rep. 10:201912020. View Article : Google Scholar : PubMed/NCBI | |
|
Entrenas Castillo M, Entrenas Costa LM, Vaquero Barrios JM, Alcalá Díaz JF, López Miranda J, Bouillon R and Quesada Gomez JM: ‘Effect of calcifediol treatment and best available therapy versus best available therapy on intensive care unit admission and mortality among patients hospitalized for COVID-19: A pilot randomized clinical study’. J Steroid Biochem Mol Biol. 203:1057512020. View Article : Google Scholar : PubMed/NCBI | |
|
Tan CW, Ho LP, Kalimuddin S, Cherng BPZ, Teh YE, Thien SY, Wong HM, Tern PJW, Chandran M, Chay JWM, et al: Cohort study to evaluate the effect of vitamin D, magnesium, and vitamin B12 in combination on progression to severe outcomes in older patients with coronavirus (COVID-19). Nutrition. 79-80:1110172020. View Article : Google Scholar : PubMed/NCBI | |
|
Jakovac H: COVID-19 and vitamin D-Is there a link and an opportunity for intervention? Am J Physiol Endocrinol Metab. 318:E5892020. View Article : Google Scholar : PubMed/NCBI | |
|
Ahmed F: A network-based analysis reveals the mechanism underlying vitamin D in suppressing cytokine storm and virus in SARS-CoV-2 infection. Front Immunol. 11:5904592020. View Article : Google Scholar : PubMed/NCBI | |
|
Aygun H: Vitamin D can prevent COVID-19 infection-induced multiple organ damage. Naunyn Schmiedebergs Arch Pharmacol. 393:1157–1160. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Kumar R, Rathi H, Haq A, Wimalawansa SJ and Sharma A: Putative roles of vitamin D in modulating immune response and immunopathology associated with COVID-19. Virus Res. 292:1982352021. View Article : Google Scholar : PubMed/NCBI | |
|
Verdoia M, Pergolini P, Nardin M, Rolla R, Negro F, Kedhi E, Suryapranata H, Marcolongo M, Carriero A and De Luca G; Novara Atherosclerosis Study Group (NAS), : Vitamin D levels and platelet reactivity in diabetic patients receiving dual antiplatelet therapy. Vascul Pharmacol. 120:1065642019. View Article : Google Scholar : PubMed/NCBI | |
|
Zabetakis I, Lordan R, Norton C and Tsoupras A: COVID-19: The inflammation link and the role of nutrition in potential mitigation. Nutrients. 12:14662020. View Article : Google Scholar : PubMed/NCBI | |
|
McCreadie RG; Scottish Schizophrenia Lifestyle Group, : Diet, smoking and cardiovascular risk in people with schizophrenia: Descriptive study. Br J Psychiatry. 183:534–539. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Henderson DC, Borba CP, Daley TB, Boxill R, Nguyen DD, Culhane MA, Louie P, Cather C, Eden Evins A, Freudenreich O, et al: Dietary intake profile of patients with schizophrenia. Ann Clin Psychiatry. 18:99–105. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Amani R: Is dietary pattern of schizophrenia patients different from healthy subjects? BMC Psychiatry. 7:152007. View Article : Google Scholar : PubMed/NCBI | |
|
Dipasquale S, Pariante CM, Dazzan P, Aguglia E, McGuire P and Mondelli V: The dietary pattern of patients with schizophrenia: A systematic review. J Psychiatr Res. 47:197–207. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Firth J, Stubbs B, Teasdale SB, Ward PB, Veronese N, Shivappa N, Hebert JR, Berk M, Yung AR and Sarris J: Diet as a hot topic in psychiatry: A population-scale study of nutritional intake and inflammatory potential in severe mental illness. World Psychiatry. 17:365–367. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Teasdale SB, Ward PB, Samaras K, Firth J, Stubbs B, Tripodi E and Burrows TL: Dietary intake of people with severe mental illness: Systematic review and meta-analysis. Br J Psychiatry. 214:251–259. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Milanski M, Degasperi G, Coope A, Morari J, Denis R, Cintra DE, Tsukumo DM, Anhe G, Amaral ME, Takahashi HK, et al: Saturated fatty acids produce an inflammatory response predominantly through the activation of TLR4 signaling in hypothalamus: Implications for the pathogenesis of obesity. J Neurosci. 29:359–370. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Patterson E, Wall R, Fitzgerald GF, Ross RP and Stanton C: Health implications of high dietary omega-6 polyunsaturated Fatty acids. J Nutr Metab. 2012:5394262012. View Article : Google Scholar : PubMed/NCBI | |
|
Jump DB, Botolin D, Wang Y, Xu J and Christian B: Fatty acids and gene transcription. Food Nutr Res. 50 (Suppl 2):5–12. 2006. View Article : Google Scholar | |
|
Stienstra R, Duval C, Müller M and Kersten S: PPARs, obesity, and inflammation. PPAR Res. 2007:959742007. View Article : Google Scholar : PubMed/NCBI | |
|
Muralikumar S, Vetrivel U, Narayanasamy A and N Das U: Probing the intermolecular interactions of PPARγ-LBD with polyunsaturated fatty acids and their anti-inflammatory metabolites to infer most potential binding moieties. Lipids Health Dis. 16:172017. View Article : Google Scholar : PubMed/NCBI | |
|
Choi GJ, Kim HM and Kang H: The potential role of dyslipidemia in COVID-19 severity: An umbrella review of systematic reviews. J Lipid Atheroscler. 9:435–448. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, et al: Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. Lancet. 395:1054–1062. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Perona JS: Membrane lipid alterations in the metabolic syndrome and the role of dietary oils. Biochim Biophys Acta Biomembr. 1859 (9 Pt B). 1690–1703. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Oruch R, Lund A, Pryme IF and Holmsen H: An intercalation mechanism as a mode of action exerted by psychotropic drugs: Results of altered phospholipid substrate availabilities in membranes? J Chem Biol. 3:67–88. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Leguisamo NM, Lehnen AM, Machado UF, Okamoto MM, Markoski MM, Pinto GH and Schaan BD: GLUT4 content decreases along with insulin resistance and high levels of inflammatory markers in rats with metabolic syndrome. Cardiovasc Diabetol. 11:1002012. View Article : Google Scholar : PubMed/NCBI | |
|
Bousquet J, Anto JM, Iaccarino G, Czarlewski W, Haahtela T, Anto A, Akdis CA, Blain H, Canonica GW, Cardona V, et al: Is diet partly responsible for differences in COVID-19 death rates between and within countries? Clin Transl Allergy. 10:162020. View Article : Google Scholar : PubMed/NCBI | |
|
Jakovac H: COVID-19: Is the ACE2 just a foe? Am J Physiol Lung Cell Mol Physiol. 318:L1025–L1026. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Warner FJ, Rajapaksha H, Shackel N and Herath CB: ACE2: From protection of liver disease to propagation of COVID-19. Clin Sci (Lond). 134:3137–3158. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Gohil K, Samson R, Dastager S and Dharne M: Probiotics in the prophylaxis of COVID-19: Something is better than nothing. 3 Biotech. 11:12021. View Article : Google Scholar : PubMed/NCBI | |
|
Karl JP: Gut Microbiota-targeted interventions for reducing the incidence, duration, and severity of respiratory tract infections in healthy non-elderly adults. Mil Med. 186:e310–e318. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Hamida RS, Shami A, Ali MA, Almohawes ZN, Mohammed AE and Bin-Meferij MM: Kefir: A protective dietary supplementation against viral infection. Biomed Pharmacother. 133:1109742021. View Article : Google Scholar : PubMed/NCBI | |
|
Abdulah DM and Hassan AB: Relation of dietary factors with infection and mortality rates of COVID-19 across the World. J Nutr Health Aging. 24:1011–1018. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Falagas ME and Kompoti M: Obesity and infection. Lancet Infect Dis. 6:438–446. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Karlsson EA and Beck MA: The burden of obesity on infectious disease. Exp Biol Med (Maywood). 235:1412–1424. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Li P, Yin YL, Li D, Kim SW and Wu G: Amino acids and immune function. Br J Nutr. 98:237–252. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Jenkins DJA, Srichaikul KK, Kendall CWC and Sievenpiper JL: Bean, fruit, and vegetable fiber, but not cereal fiber are associated with reduced mortality in Japan. Am J Clin Nutr. 111:941–943. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Gill SK, Rossi M, Bajka B and Whelan K: Dietary fibre in gastrointestinal health and disease. Nat Rev Gastroenterol Hepatol. 18:101–116. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Yao T, Chen MH and Lindemann SR: Structurally complex carbohydrates maintain diversity in gut-derived microbial consortia under high dilution pressure. FEMS Microbiol Ecol. 96:fiaa1582020. View Article : Google Scholar : PubMed/NCBI | |
|
Vanable PA, Carey MP, Carey KB and Maisto SA: Smoking among psychiatric outpatients: Relationship to substance use, diagnosis, and illness severity. Psychol Addict Behav. 17:259–265. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
de Leon J and Diaz FJ: A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviors. Schizophr Res. 76:135–157. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Gilbody S, Peckham E, Bailey D, Arundel C, Heron P, Crosland S, Fairhurst C, Hewitt C and Li J; members of the SCIMITAR+ collaborative, : Smoking cessation in severe mental illness: Combined long-term quit rates from the UK SCIMITAR trials programme. Br J Psychiatry. 18:95–97. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Thomson D, Berk M, Dodd S, Rapado-Castro M, Quirk SE, Ellegaard PK, Berk L and Dean OM: Tobacco use in bipolar disorder. Clin Psychopharmacol Neurosci. 13:1–11. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Li XH, An FR, Ungvari GS, Ng CH, Chiu HFK, Wu PP, Jin X and Xiang YT: Prevalence of smoking in patients with bipolar disorder, major depressive disorder and schizophrenia and their relationships with quality of life. Sci Rep. 7:84302017. View Article : Google Scholar : PubMed/NCBI | |
|
Arnson Y, Shoenfeld Y and Amital H: Effects of tobacco smoke on immunity, inflammation and autoimmunity. J Autoimmun. 34:J258–J265. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Lee J, Taneja V and Vassallo R: Cigarette smoking and inflammation: Cellular and molecular mechanisms. J Dent Res. 91:142–149. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Cattaruzza MS, Zagà V, Gallus S, D'Argenio P and Gorini G: Tobacco smoking and COVID-19 pandemic: Old and new issues. A summary of the evidence from the scientific literature. Acta Biomed. 91:106–112. 2020.PubMed/NCBI | |
|
Polverino F: Cigarette smoking and COVID-19: A complex interaction. Am J Respir Crit Care Med. 202:471–472. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Reddy RK, Charles WN, Sklavounos A, Dutt A, Seed PT and Khajuria A: The effect of smoking on COVID-19 severity: A systematic review and meta-analysis. J Med Virol. 93:1045–1056. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Lombardi C, Roca E, Ventura L and Cottini M: Smoking and COVID-19, the paradox to discover: An Italian retrospective, observational study in hospitalized and non-hospitalized patients. Med Hypotheses. 146:1103912021. View Article : Google Scholar : PubMed/NCBI | |
|
Usman MS, Siddiqi TJ, Khan MS, Patel UK, Shahid I, Ahmed J, Kalra A and Michos ED: Is there a smoker's paradox in COVID-19? BMJ Evid Based Med. Aug 11–2020.(Epub ahead of print). View Article : Google Scholar : PubMed/NCBI | |
|
Edmonston DL, South AM, Sparks MA and Cohen JB: Coronavirus disease 2019 and hypertension: The role of angiotensin-converting enzyme 2 and the renin-angiotensin system. Adv Chronic Kidney Dis. 27:404–411. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Vleeming W, Rambali B and Opperhuizen A: The role of nitric oxide in cigarette smoking and nicotine addiction. Nicotine Tob Res. 4:341–348. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Akerström S, Mousavi-Jazi M, Klingström J, Leijon M, Lundkvist A and Mirazimi A: Nitric oxide inhibits the replication cycle of severe acute respiratory syndrome coronavirus. J Virol. 79:1966–1969. 2005. View Article : Google Scholar | |
|
Czuczwar M, Kiś J, Czuczwar P, Wielosz M and Turski W: Nicotine diminishes anticonvulsant activity of antiepileptic drugs in mice. Pol J Pharmacol. 55:799–802. 2003.PubMed/NCBI | |
|
Reinsberger C, Dorn T and Krämer G: Smoking reduces serum levels of lamotrigine. Seizure. 17:651–653. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Tsuda Y, Saruwatari J and Yasui-Furukori N: Meta-analysis: The effects of smoking on the disposition of two commonly used antipsychotic agents, olanzapine and clozapine. BMJ Open. 4:e0042162014. View Article : Google Scholar : PubMed/NCBI | |
|
Oliveira P, Ribeiro J, Donato H and Madeira N: Smoking and antidepressants pharmacokinetics: A systematic review. Ann Gen Psychiatry. 16:172017. View Article : Google Scholar : PubMed/NCBI | |
|
Bobes J, Arango C, Garcia-Garcia M and Rejas J: Healthy lifestyle habits and 10-year cardiovascular risk in schizophrenia spectrum disorders: An analysis of the impact of smoking tobacco in the CLAMORS schizophrenia cohort. Schizophr Res. 119:101–109. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Chao AM, White MA, Grilo CM and Sinha R: Examining the effects of cigarette smoking on food cravings and intake, depressive symptoms, and stress. Eat Behav. 24:61–65. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Alsuwaidan MT, Kucyi A, Law CW and McIntyre RS: Exercise and bipolar disorder: A review of neurobiological mediators. Neuromolecular Med. 11:328–336. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Sylvia LG, Ametrano RM and Nierenberg AA: Exercise treatment for bipolar disorder: Potential mechanisms of action mediated through increased neurogenesis and decreased allostatic load. Psychother Psychosom. 79:87–96. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Kay-Lambkin FJ, Thornton L, Lappin JM, Hanstock T, Sylvia L, Jacka F, Baker AL, Berk M, Mitchell PB, Callister R, et al: Study protocol for a systematic review of evidence for lifestyle interventions targeting smoking, sleep, alcohol/other drug use, physical activity, and healthy diet in people with bipolar disorder. Syst Rev. 5:1062016. View Article : Google Scholar : PubMed/NCBI | |
|
Cuomo A, Giordano N, Goracci A and Fagiolini A: Depression and vitamin D deficiency: Causality, assessment, and clinical practice implications. Neuropsychiatry (London). 7:606–614. 2017. | |
|
Cuomo A, Maina G, Bolognesi S, Rosso G, Beccarini Crescenzi B, Zanobini F, Goracci A, Facchi E, Favaretto E, Baldini I, et al: Prevalence and correlates of vitamin D deficiency in a sample of 290 inpatients with mental Illness. Front Psychiatry. 10:1672019. View Article : Google Scholar : PubMed/NCBI | |
|
Hansdottir S, Monick MM, Lovan N, Powers LS and Hunninghake GW: Smoking disrupts vitamin D metabolism in the lungs. Am J Respir Crit Care Med. 181:A14252010. | |
|
Lange NE, Sparrow D, Vokonas P and Litonjua AA: Vitamin D deficiency, smoking, and lung function in the normative aging study. Am J Respir Crit Care Med. 186:616–621. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Uh ST, Koo SM, Kim YK, Kim KU, Park SW, Jang AS, Kim DJ, Kim YH and Park CS: Inhibition of vitamin D receptor translocation by cigarette smoking extracts. Tuberc Respir Dis (Seoul). 73:258–265. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Gejman PV, Sanders AR and Duan J: The role of genetics in the etiology of schizophrenia. Psychiatr Clin North Am. 33:35–66. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Kerner B: Genetics of bipolar disorder. Appl Clin Genet. 7:33–42. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Shadrina M, Bondarenko EA and Slominsky PA: Genetics factors in major depression disease. Front Psychiatry. 9:3342018. View Article : Google Scholar : PubMed/NCBI | |
|
Kaser A: Genetic risk of severe covid-19. N Engl J Med. 383:1590–1591. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Pairo-Castineira E, Clohisey S, Klaric L, Bretherick AD, Rawlik K, Pasko D, Walker S, Parkinson N, Fourman MH, Russell CD, et al: Genetic mechanisms of critical illness in Covid-19. Nature. 591:92–98. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Zeberg H and Pääbo S: The major genetic risk factor for severe COVID-19 is inherited from Neanderthals. Nature. 587:610–612. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P and Soubrier F: An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest. 86:1343–1346. 1990. View Article : Google Scholar : PubMed/NCBI | |
|
Wu Y, Wang X, Shen X, Tan Z and Yuan Y: The I/D polymorphism of angiotensin-converting enzyme gene in major depressive disorder and therapeutic outcome: A case-control study and meta-analysis. J Affect Disord. 136:971–978. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Kucukali CI, Aydin M, Ozkok E, Bilge E, Zengin A, Cakir U and Kara I: Angiotensin-converting enzyme polymorphism in schizophrenia, bipolar disorders, and their first-degree relatives. Psychiatr Genet. 20:14–19. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Mazaheri H and Saadat M: Association between insertion/deletion polymorphism in angiotension converting enzyme and susceptibility to schizophrenia. Iran J Public Health. 44:369–373. 2015.PubMed/NCBI | |
|
Crescenti A, Gassó P, Mas S, Abellana R, Deulofeu R, Parellada E, Bernardo M and Lafuente A: Insertion/deletion polymorphism of the angiotensin-converting enzyme gene is associated with schizophrenia in a Spanish population. Psychiatry Res. 165:175–180. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Song GG and Lee YH: The insertion/deletion polymorphism in the angiotensin-converting enzyme and susceptibility to schizophrenia or Parkinson's disease: A meta-analysis. J Renin Angiotensin Aldosterone Syst. 16:434–442. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Nadalin S, Buretić-Tomljanović A, Rubeša G, Jonovska S, Tomljanović D and Ristić S: Angiotensin-converting enzyme gene insertion/deletion polymorphism is not associated with schizophrenia in a Croatian population. Psychiatr Genet. 22:267–268. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Hui L, Wu JQ, Zhang X, Lv J, Du WL, Kou CG, Yu YQ, Lv MH, Chen DC and Zhang XY: Association between the angiotensin-converting enzyme gene insertion/deletion polymorphism and first-episode patients with schizophrenia in a Chinese Han population. Hum Psychopharmacol. 29:274–279. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Hui L, Wu JQ, Ye MJ, Zheng K, He JC, Zhang X, Liu JH, Tian HJ, Gong BH, Chen DC, et al: Association of angiotensin-converting enzyme gene polymorphism with schizophrenia and depressive symptom severity in a Chinese population. Hum Psychopharmacol. 30:100–107. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Baghai TC, Schule C, Zwanzger P, Minov C, Zill P, Ella R, Eser D, Oezer S, Bondy B and Rupprecht R: Hypothalamic-pituitary-adrenocortical axis dysregulation in patients with major depression is influenced by the insertion/deletion polymorphism in the angiotensin I-converting enzyme gene. Neurosci Lett. 328:299–303. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Bahramali E, Firouzabadi N, Yavarian I, Shayesteh MR, Erfani N, Shoushtari AA and Asadpour R: Influence of ACE gene on differential response to sertraline versus fluoxetine in patients with major depression: A randomized controlled trial. Eur J Clin Pharmacol. 72:1059–1064. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Delanghe JR, Speeckaert MM and De Buyzere M: The host's angiotensin-converting enzyme polymorphism may explain epidemiological findings in COVID-19 infections. Clin Chim Acta. 505:192–193. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Delanghe JR, Speeckaert MM and De Buyzere ML: COVID-19 infections are also affected by human ACE1 D/I polymorphism. Clin Chem Lab Med. 58:1125–1126. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Zajc Petranović M, Skarić-Jurić T, Smolej Narančić N, Tomas Z, Krajačić P, Miličić J, Barbalić M and Tomek-Roksandić S: Angiotensin-converting enzyme deletion allele is beneficial for the longevity of Europeans. Age (Dordr). 34:583–595. 2012. View Article : Google Scholar | |
|
Bellone M and Calvisi SL: ACE polymorphisms and COVID-19-related mortality in Europe. J Mol Med (Berl). 98:1505–1509. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Hatami N, Ahi S, Sadeghinikoo A, Foroughian M, Javdani F, Kalani N, Fereydoni M, Keshavarz P and Hosseini A: Worldwide ACE (I/D) polymorphism may affect COVID-19 recovery rate: An ecological meta-regression. Endocrine. 68:479–484. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Jakovac H: COVID-19 and hypertension: Is the HSP60 culprit for the severe course and worse outcome? Am J Physiol Heart Circ Physiol. 319:H793–H796. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Meng J, Xiao G, Zhang J, He X, Ou M, Bi J, Yang R, Di W, Wang Z, Li Z, et al: Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension. Emerg Microbes Infect. 9:757–760. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Pirola CJ and Sookoian S: Estimation of Renin-Angiotensin-Aldosterone-System (RAAS)-Inhibitor effect on COVID-19 outcome: A Meta-analysis. J Infect. 81:276–281. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Zhong Y, Zhao L, Wu G, Hu C, Wu C, Xu M, Dong H, Zhang Q, Wang G, Yu B, et al: Impact of renin-angiotensin system inhibitors use on mortality in severe COVID-19 patients with hypertension: A retrospective observational study. J Int Med Res. 48:3000605209791512020. View Article : Google Scholar : PubMed/NCBI | |
|
Cetinkal G, Kocas BB, Ser OS, Kilci H, Yildiz SS, Ozcan SN, Verdi Y, Altinay M and Kilickesmez K: The association between chronic use of renin-angiotensin-aldosterone system blockers and in-hospital adverse events among covid-19 patients with hypertension. Sisli Etfal Hastan Tip Bul. 54:399–404. 2020.PubMed/NCBI | |
|
Lee MMY, Docherty KF, Sattar N, Mehta N, Kalra A, Nowacki AS, Solomon SD, Vaduganathan M, Petrie MC, Jhund PS and McMurray JJV: Renin-angiotensin system blockers, risk of SARS-CoV-2 infection and outcomes from CoViD-19: Systematic review and meta-analysis. Eur Heart J Cardiovasc Pharmacother pvaa138. 2020.(Epub ahead of prin). View Article : Google Scholar | |
|
Niederhofer H: Angiotensin converting enzyme inhibitors/estrogen/cortisol: Maybe an additional option in the treatment of psychiatrically disordered patients? Med Hypotheses. 70:703–704. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Gadelha A, Vendramini AM, Yonamine CM, Nering M, Berberian A, Suiama MA, Oliveira V, Lima-Landman MT, Breen G, Bressan RA, et al: Convergent evidences from human and animal studies implicate angiotensin I-converting enzyme activity in cognitive performance in schizophrenia. Transl Psychiatry. 5:e6912015. View Article : Google Scholar : PubMed/NCBI | |
|
Wincewicz D and Braszko JJ: Validation of brain angiotensin system blockade as a novel drug target in pharmacological treatment of neuropsychiatric disorders. Pharmacopsychiatry. 50:233–247. 2017. View Article : Google Scholar : PubMed/NCBI |
